Schizophrenia is a psychiatric disorder with a complicated pathophysiology, involving many biochemical abnormalities in the brain. Because neuroactive steroids (NASs) modulate neurotransmitter systems that are implicated in the pathology of schizophrenia, recent research has focused on examining the role that NASs play in the illness. Although research in this area is relatively new, it appears that NASs may potentially be implicated in the pathophysiology of the illness. This paper reviews the current understanding of NASs, the research literature on NASs in schizophrenia and in animal models of the illness (including the effects of antipsychotic medication on NASs) and on the potential antipsychotic role of NASs themselves and, finally, discusses future directions for this area of schizophrenia research.
RupprechtRHolsboerF.Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci1999;22:410–16.
7.
HojoYHattoriT-AEnamiTFurukawaASuzukiKIshiiH-T, and others. Adult male rat hippocampus synthesizes estradiol from pregnenolone by P45017 abd p450 aromatase localized in neurons. Proc Natl Acad Sci2004;101:865–70.
8.
Stoffel–WagnerB.Neurosteroid metabolism in the human brain. Eur J Endocrinol2001;145:669–79.
9.
Stoffel-WagnerB.Neurosteroid biosynthesis in the human brain and its clinical implications. Ann N Y Acad Sci2003;1007:64–78.
10.
O'DellLEAlomaryAAValléeMKoobGFFitzgeraldRLPurdyRH. Ethanol-induced increases in neuroactive steroids in the rat brain and plasma are absent in adrenalectomized and gonadectomized rats. Eur J Pharmacol2004;484:241–7.
11.
RupprechtRReulJMTrappTvan SteenselBWetzelCDammK, and others. Progesterone receptor-mediated effects of neuroactive steroids. Neuron1993;11:523–30.
12.
RupprechtR.The neuropsychopharmacological potential of neuroactive steroids. J Psychiar Rest1997;31:297–314.
13.
RupprechtRHolsboerF.Neuroactive steroids in neuropsychopharmacology. Int Rev Neurobiol2001;46:461–77.
14.
FollesaPConcasAPorcuPSannaESerraMMostallinoMC, and others. Role of allopregnanolone in the regulation of GABAA receptor plasticity during long-term exposure to and withdrawal from progesterone. Brain Res Brain Res Rev2001;37:81–90.
15.
ZinderODarDE. Neuroactive steroids: Their mechanism of action and their function in the stress response. Acta Physiol Scand1999;167:181–8.
16.
MacdonaldRLOlsenRW. GABAA receptor channels. Annu Rev Neurosci1994;17:569–602.
17.
TwymanREMacdonaldRL. Neurosteroid regulation of GABAA receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J Physiol1992;456:215–45.
18.
Le MellédoJ-MBakerGB. Neuroactive steroids and anxiety disorders. J Psychiatry Neurosci2002;27:161–5.
19.
LundgrenPStrömbergJBäckströmTWangM.Allopregnanolone-stimulated GABA-mediated chloride ion flux is inhibited by 3 -hydroxy-5 -pregnan-20-one (isoallopregnanolone). Brain Res2003;982:45–53.
20.
PrinceRJSimmondsMA. 5-beta-Pregnan-3-beta-ol-20-one, a specific antagonist at the neurosteroid site of the GABAA receptor-complex. Neurosci Lett1992;135:273–5.
21.
PrinceRJSimmondsMA. Differential antagonism by epipregnanolone of alphaxalone and pregnanolone potentiation of [3H]flunitrazepam binding suggests more than one class of binding site for steroids at GABAA receptors. Neuropharmacology1993;32:59–63.
22.
NestlerEJHymanSEMalenkaRC, editor. Molecular neuropharmacology: A foundation for clinical neuroscience. New York (NY): McGraw-Hill; 2001.
23.
ImamuraMPrasadC.Modulation of GABA-gated chloride influx in the brain by dehydroepiandrosterone and its metabolites. Biochem Biophys Res Commun1998;243:771–5.
24.
Park-ChungMMalayevAPurdyRHGibbsTTFarbDH. Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites. Brain Res1999;830:72–87.
25.
BaulieuEERobelP.Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc Natl Acad Sci USA1998;95:4089–91.
26.
RupprechtR.Neuroactive steroids: Mechanism of action and neuropsychopharmacological properties. Psychoneuroendocrinology2003;28:139–68.
27.
TourneyGErbJL. Temporal variation in androgens and stress hormones in control and schizophrenic subjects. Biol Psychiatry1979;14:395–404.
28.
MarxCETrostWTShampineLJLiebermanJAMorrowALThakoreJH. Neuroactive steroids in schizophrenia: Relevance to symptoms and therapeutics. Biol Psychiatry2004;55(suppl 8):171.
29.
OadesRDSchepkerR.Serum gonadal steroids in young schizophrenic patients. Psychoneuroendochrinology1994;19:373–85.
30.
ShirayamaYHashimotoKSuzukiYHiguchiT.Correlation of plasma neurosteroids to the severity of negative symptoms in male patients with schizophrenia. Schizophrenia Res2002;58:69–74.
31.
RitsnerMMaayanRGibelAStrousRDModaiIWeizmanA.Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol2004;14:267–73.
32.
BreierABuchananRW. The effects of metabolic stress on plasma progesterone levels in healthy volunteers and schizophrenic patients. Life Sci1992;51:1527–34.
33.
PriorTITibboPGPurdonSE. Elevated progesterone levels correlate with symptom severity in males newly diagnosed with schizophrenia or schizophreniform disorder. Proceeding of the Canadian College of Neuropsychopharmacology; June, 2003; Montreal (QC).
34.
TaherianfardMShariatyM.Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci2004;58:3–9.
35.
TibboPSwainsonJChuePLe MellédoJ-M.Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia. Depress Anxiety2003;17:65–72.
36.
BarbacciaMDAffricanoDPurdyRHMacioccoESpigaFBiggioG.Clozapine, but not haloperidol, increases brain concentrations of neuroactive steroids in the rat. Neuropsychopharmacology2001;25:489–97.
37.
MarxCEDuncanGEGilmoreJHLiebermanJAMorrowAL. Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol Psychiatry2000;47:1000–4.
38.
MarxCEVanDorenMJDuncanGELiebermanJAMorrowAL. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacol2003;28:1–13.
39.
NechmadAMaayanRRamadanEMoradOPoyurovskyMWeizmanA.Clozapine decreases rat brain dehydroepiandrosterone and dehydroepiandrosterone sulfate levels. Eur Neuropsychopharmacol2003;13:29–31.
40.
BenesFMBerrettaS.GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology2001;25:1–27.
41.
MotzoCPorcedduMLMairaGFloreGConcasADazziL, and others. Inhibition of basal and stress-induced dopamine release in the cerebral cortex and nucleus accumbens of freely moving rats by the neurosterid allopregnanolone. J Psychopharmacol1996;10:266–72.
42.
KhistiRTMandhaneSNChopdeCT. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one induces catalepsy in mice. Neurosci Lett1998;251:85–8.
43.
KhistiRTDeshpandeLSChopdeCT. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one affects dopamine-mediated behavior in rodents. Psychopharmacology (Berl)2002;161:120–8.
44.
UgaleRRHiraniKMorelliMChopdeCT. Role of Neuroactive Steroid Allopregnanolone in Antipsychotic-like Action of Olanzapine in Rodents. Neuropsychopharmacology2004:29:1597–609.
45.
WenSDongKOnolfoJPVincensM.Treatment with dehydroepiandrosterone sulfate increases NMDA receptors in hippocampus and cortex. Eur J Pharmacol2001;430:373–4.
46.
MajewskaMD. Neurosteroid antagonists of the GABAA receptors. In: BaulieuE-ERobelPSchumacherM, editors. Neurosteroids: A new regulatory function in the nervous system. Totawa (NJ): Humana Press Inc; 1999. p 155–66.
47.
MiyamotoSLaMantiaASDuncanGESullivanPGilmoreJHLiebermanJA. Recent advances in the neurobiology of schizophrenia. Mol Interv2003;3:27–39.
48.
HarrisDDWolkowitzOMReusVI. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J Biol Psychiatry2001;2:99–102.
49.
StraussEBSandsDERobinsonAMTandallWJStevensonWAH. Use of dehydroepiandrosterone in psychiatric treatment: A preliminary survey. Br Med J1952;2:64–6.
50.
StrousRDMaayanRLapidusRStryjerRLustigMKotlerM, and others. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry2003;60:133–41.
51.
HallonquistJDSeemanMVLangMRectorNA. Variation in symptom severity over the menstrual cycle of schizophrenics. Biol Psychiatry1993;33:207–9.
52.
HäfnerHRiecher-RösslerAAn Der HeidenWMaurerKFätkenheuerBLöfflerW.Generating and testing a causal explanation of the gender differences in age at first onset of schizophrenia. Psychol Med1993;23:925–40.
53.
RupprechtRKochMMontkowskiALancelMFaulhaberJHartingJ, and others. Assessment of neuroleptic-like properties of progesterone. Psychopharmacology (Berl)1999;143:29–38.
